10-Q: Quanterix Reports Mixed Q2 Results: Consumables Growth Offsets Instrument Sales Decline

Quanterix saw a modest increase in total revenue for Q2 2024, driven by consumables and service growth, but experienced a decline in instrument sales.

Summary

• Quanterix reported a total revenue of $34.4 million for the second quarter of 2024, an 11% increase compared to $31.0 million in the same period last year.
• Product revenue was $19.9 million, with a $2.2 million increase in consumables demand offset by a $1.2 million decrease in instrument sales.
• Service revenue grew by 28% to $13.5 million, primarily due to a $2.6 million increase in Accelerator Laboratory revenue.
• The company experienced a net loss of $9.5 million for the quarter, compared to a net loss of $6.1 million in Q2 2023.
• For the first six months of 2024, total revenue was $66.4 million, a 12% increase from $59.5 million in the first half of 2023.
• The net loss for the first half of 2024 was $19.5 million, compared to a net loss of $12.2 million for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $296.9 million as of June 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth in consumables and services, but also increased losses and a decline in instrument sales. The company is facing challenges in the current capital funding environment and has ongoing material weaknesses in internal controls, which tempers the overall sentiment.

Positives

• Consumables revenue increased due to higher demand and selling prices.
• Accelerator Laboratory services saw significant growth, driven by higher volumes and prices.
• The company launched new Simoa Advantage PLUS assays, improving manufacturing and consistency.
• The Lucent AD p-Tau 217 blood test received Breakthrough Device designation from the FDA, potentially accelerating its path to market.

Negatives

• Instrument sales decreased by $1.2 million in Q2 2024 due to a constrained capital funding environment.
• The company's net loss increased to $9.5 million in Q2 2024, compared to $6.1 million in Q2 2023.
• Research and development expenses increased by 36% in Q2 2024, driven by increased headcount and outside services.
• Selling, general, and administrative expenses increased by 12% in Q2 2024, primarily due to increased compensation and stock-based compensation costs.

Risks

• The company expects softness in instrument sales to continue for the remainder of 2024 due to a constrained capital funding environment.
• The company anticipates continued operating losses and significant expenses for at least the next 24 months.
• The company's future capital requirements depend on various factors, including market acceptance of products and regulatory requirements.
• The company may need to raise additional capital if existing funds are insufficient, which could lead to dilution or unfavorable terms.
• The company's internal control over financial reporting was not effective at a reasonable assurance level as of June 30, 2024, due to material weaknesses.

Future Outlook

The company expects continued growth in Accelerator Laboratory services through 2024, but anticipates softness in instrument sales for the remainder of 2024 due to a constrained capital funding environment. They also expect to incur significant expenses and operating losses for at least the next 24 months.

Industry Context

The report reflects a trend in the life sciences industry where companies are increasingly focusing on recurring revenue streams from consumables and services, while facing challenges in capital equipment sales due to funding constraints. The company's focus on developing advanced diagnostic tests aligns with the industry's shift towards early detection and personalized medicine.

Comparison to Industry Standards

• Quanterix's revenue growth of 11% in Q2 2024 is moderate compared to some high-growth biotech companies, but is solid considering the current capital funding environment.
• The company's focus on consumables and service revenue is similar to other life science tool companies like Illumina and Thermo Fisher Scientific, which also rely on recurring revenue from their installed base.
• The development of the Lucent AD p-Tau 217 blood test and its Breakthrough Device designation is comparable to other companies developing novel diagnostic tests for Alzheimer's disease, such as C2N Diagnostics and Roche.
• The company's net loss is typical for a growth-stage biotech company investing heavily in R&D and commercialization, similar to companies like Exact Sciences and Bio-Rad Laboratories in their early stages.

Related Party Transactions

• The company has related party transactions with Tufts University, Harvard University, Mass General Brigham, and UltraDx Limited.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the potential need for additional capital raises.
• Employees may be impacted by the company's ongoing efforts to remediate material weaknesses in internal control over financial reporting.
• Customers may benefit from the improved Simoa Advantage PLUS assays and the growth in Accelerator Laboratory services.
• Suppliers may be impacted by the company's purchase commitments and ongoing manufacturing activities.

Next Steps

• The company will continue to transition existing assays to Advantage PLUS.
• The company will continue to invest in new instrument and assay development.
• The company will continue to implement remediation efforts to address material weaknesses in internal control over financial reporting.
• The company will continue to evaluate alternatives for two leased office and laboratory facilities, including sub-leasing.

Key Dates

Keywords

immunoassay, biomarkers, diagnostics, Simoa, Lucent Diagnostics, research services, consumables, instruments, Accelerator Laboratory, FDA, p-Tau 217, Alzheimer's disease